An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: Actions of TNP-470, marimastat and the tubulin-binding agent Ang-510

Biochemical and Biophysical Research Communications

Volumn 391, Issue 2, 2010, Pages 1161-1165

  van Wijngaarden, Jens ^a   Snoeks, Thomas J A ^a   van Beek, Ermond ^a   Bloys, Henny ^a   Kaijzel, Eric L ^a   van Hinsbergh, Victor W M ^b   Löwik, Clemens W G M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; In vitro assay; Tubulin binding; Vascular disruption

Indexed keywords

ANG 510; FUMAGILLOL CHLOROACETYLCARBAMATE; MARIMASTAT; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FETUS; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZENE DERIVATIVES; CAPILLARIES; CYCLOHEXANES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HYDROXAMIC ACIDS; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; SESQUITERPENES; TUBULIN MODULATORS;

EID: 73449097423     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.11.097     Document Type: Article

References (36)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
2. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
3. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66 (1993) 181-196
4. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333 (1995) 1757-1763
5. Ellis L.M., Liu W., Ahmad S.A., Fan F., Jung Y.D., Shaheen R.M., and Reinmuth N. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin. Oncol. 28 (2001) 94-104
6. Siemann D.W., Warrington K.H., and Horsman M.R. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother. Oncol. 57 (2000) 5-12
7. Chaplin D.J., and Dougherty G.J. Tumour vasculature as a target for cancer therapy. Br. J. Cancer 80 Suppl. 1 (1999) 57-64
8. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 9 (1990) 267-282
9. Siemann D.W. Vascular targeting agents Horizons. Cancer Ther. 3 (2002) 4-15
10. Gaya A.M., and Rustin G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin. Oncol. (R. Coll. Radiol.) 17 (2005) 277-290
11. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer 5 (2005) 423-435
12. Pilat M.J., and Lorusso P.M. Vascular disrupting agents. J. Cell. Biochem. 99 (2006) 1021-1039
13. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
14. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10 (2004) 415-427
15. Cai S.X. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat. Anticancer Drug Discov. 2 (2007) 79-101
16. Chaplin D.J., Horsman M.R., and Siemann D.W. Current development status of small-molecule vascular disrupting agents. Curr. Opin. Investig. Drugs 7 (2006) 522-528
17. Hinnen P., and Eskens F.A. Vascular disrupting agents in clinical development. Br. J. Cancer 96 (2007) 1159-1165
18. Patterson D.M., and Rustin G.J. Vascular damaging agents. Clin. Oncol. (R. Coll. Radiol.) 19 (2007) 443-456
19. Tozer G.M., Kanthou C., Lewis G., Prise V.E., Vojnovic B., and Hill S.A. Tumour vascular disrupting agents: combating treatment resistance. Br. J. Radiol. 81 Spec No. 1 (2008) S12-S20
20. Siemann D.W., and Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 60 (2004) 1233-1240
21. Siemann D.W., and Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 28 (2008) 2027-2031
22. Siemann D.W., and Horsman M.R. Vascular targeted therapies in oncology. Cell Tissue Res. 335 (2009) 241-248
23. Deckers M., van der P.G., Dooijewaard S., Kroon M., van Hinsbergh V., Papapoulos S., and Lowik C. Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants. Lab. Invest. 81 (2001) 5-15
24. Burbridge M.F., Coge F., Galizzi J.P., Boutin J.A., West D.C., and Tucker G.C. The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis 5 (2002) 215-226
25. Friis T., Hansen A.B., Houen G., and Engel A.M. Influence of angiogenesis inhibitors on endothelial cell morphology in vitro. APMIS 114 (2006) 211-224
26. Lien W.H., Chen C.K., Lai L.Y., Chen Y.H., Wu M.P., and Wu L.W. Participation of cyclin D1 deregulation in TNP-470-mediated cytostatic effect: involvement of senescence. Biochem. Pharmacol. 68 (2004) 729-738
27. Yeh J.R., Mohan R., and Crews C.M. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc. Natl. Acad. Sci. USA 97 (2000) 12782-12787
28. Zhang Y., Griffith E.C., Sage J., Jacks T., and Liu J.O. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. USA 97 (2000) 6427-6432
29. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 9 (2005) 267-285
30. Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., Brown P.D., and Giavazzi R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. 87 (1995) 293-298
31. Kusaka M., Sudo K., Matsutani E., Kozai Y., Marui S., Fujita T., Ingber D., and Folkman J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer 69 (1994) 212-216
32. Iyer S., Chaplin D.J., Rosenthal D.S., Boulares A.H., Li L.Y., and Smulson M.E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58 (1998) 4510-4514
33. Zhu W.H., Guo X., Villaschi S., and Francesco N.R. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab. Invest. 80 (2000) 545-555
34. Chaplin D.J., Pettit G.R., and Hill S.A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 19 (1999) 189-195
35. Galbraith S.M., Chaplin D.J., Lee F., Stratford M.R., Locke R.J., Vojnovic B., and Tozer G.M. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21 (2001) 93-102
36. Grosios K., Holwell S.E., McGown A.T., Pettit G.R., and Bibby M.C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 81 (1999) 1318-1327